Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
BELLICUM PHARMACEUTICALS, INC (BLCM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/10/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 06/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 05/05/2023 |
3
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 3 on BELLICUM PHARMACEUTICALS, INC |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 10% stake in BELLICUM PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| Ikarian Capital, LLC reports a 5.2% stake in BELLICUM PHARMACEUTICALS, INC. |
| 01/20/2023 |
4/A
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 80,968 shares
@ $0 |
|
| 01/05/2023 |
4
| Daly James M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 60,414 shares
@ $0 |
|
| 01/05/2023 |
4
| DAVIS STEPHEN (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 74,739 shares
@ $0 |
|
| 01/05/2023 |
4
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 87,196 shares
@ $0 |
|
| 01/05/2023 |
4
| Stonehouse Jon P (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 121,452 shares
@ $0 |
|
| 01/05/2023 |
4
| Klimovsky Judith V (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 60,414 shares
@ $0 |
|
| 01/04/2023 |
4/A
| Stonehouse Jon P (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 60,580 shares
@ $0 |
|
| 12/12/2022 |
8-K
| Quarterly results |
| 12/07/2022 |
8-K
| Quarterly results |
| 11/18/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/24/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/24/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/14/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 09/02/2022 |
4
| Klimovsky Judith V (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 35,082 shares
@ $0 |
|
| 09/02/2022 |
4
| DAVIS STEPHEN (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 43,400 shares
@ $0 |
|
| 09/02/2022 |
4
| Daly James M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 35,082 shares
@ $0 |
|
| 09/02/2022 |
4
| Huber Reid M (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 46,489 shares
@ $0 |
|
| 09/02/2022 |
4
| Stonehouse Jon P (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 60,580 shares
@ $0 |
|
| 09/01/2022 |
4/A
| Stonehouse Jon P (Director) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Exercised 21,054 restricted stock units
@ $0 |
|
| 08/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/16/2022 |
4
| Fair Richard A. (President and CEO) has filed a Form 4 on BELLICUM PHARMACEUTICALS, INC|
Txns:
| Granted 400,000 options to buy
@ $1.44, valued at
$576k
|
|
|
|
|